| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Multiple targets: inflammatory mediators; microbial targets; cancer-related targets.
|
|---|---|
| ln Vitro |
The anti-cancer properties of 1αH,5αH-Guaia-6-ene-4β,10β-diol are demonstrated. IC50 values of 56.7 μM, 76.7 μM, and 59.0 μM, respectively, are observed for 1αH, 5αH-Guaia-6-ene-4β, and 10β-diol against H460, MCF-7, and PC-7.
1αH,5αH-Guaia-6-ene-4β,10β-diol exhibits biological activities typical of guaiane-type sesquiterpenoids, including anti-inflammatory, antimicrobial, and cytotoxic effects. It may inhibit the production of pro-inflammatory mediators such as NO, TNF-α, and IL-6 in activated macrophages. The compound may also show antimicrobial activity against various bacterial and fungal strains. Cytotoxic activity has been observed against cancer cell lines in some guaiane-type sesquiterpenoids. |
| ln Vivo |
In vivo studies of 1αH,5αH-Guaia-6-ene-4β,10β-diol are limited. Based on related guaiane-type sesquiterpenoids, it is expected to exhibit anti-inflammatory effects in animal models of inflammation. Antimicrobial effects may be evaluated in infection models. Further studies are needed to characterize its specific in vivo activities and pharmacokinetic properties.
|
| Enzyme Assay |
Anti-inflammatory activity is assessed by measuring the inhibition of NO production, cytokine levels (TNF-α, IL-6, IL-1β), or COX-2/iNOS expression in enzyme assays or cell-based systems. Antimicrobial activity is assessed by broth microdilution for MIC determination against bacterial and fungal strains. Cytotoxic activity is assessed by cell viability assays (MTT, SRB) using cancer cell lines.
|
| Cell Assay |
Macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS to induce inflammation, and cells are treated with the compound at various concentrations. Inflammatory mediators (NO, TNF-α, IL-6) in culture supernatant are measured by Griess reagent or ELISA. For antimicrobial studies, bacterial or fungal cultures are grown in appropriate media and treated with the compound, and growth inhibition is measured. Cancer cell lines are used for cytotoxic studies.
|
| Animal Protocol |
In vivo studies for 1αH,5αH-Guaia-6-ene-4β,10β-diol are not well documented. Potential animal models include: carrageenan-induced paw edema for anti-inflammatory evaluation; and infection models for antimicrobial evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 1αH,5αH-Guaia-6-ene-4β,10β-diol are limited. As a sesquiterpenoid, it is expected to be lipophilic with moderate oral absorption. The compound is soluble in organic solvents. Standard laboratory storage conditions apply. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 1αH,5αH-Guaia-6-ene-4β,10β-diol are limited. Sesquiterpenoids generally have moderate toxicity, with some compounds showing cytotoxic activity. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
1αH,5αH-Guaia-6-ene-4β,10β-diol is a guaiane-type sesquiterpenoid natural product. Guaiane-type sesquiterpenoids are a large class of natural products with diverse biological activities, including anti-inflammatory, antimicrobial, cytotoxic, and neuroprotective effects. This compound is of interest for natural product research and drug discovery. It is used as a reference standard and for research purposes. It is for research use only.
|
| Molecular Formula |
C15H26O2
|
|---|---|
| Molecular Weight |
238.37
|
| Exact Mass |
238.193
|
| CAS # |
2013537-81-8
|
| PubChem CID |
162639160
|
| Appearance |
White to off-white solid
|
| Boiling Point |
343.2±42.0 °C(Predicted)
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O[C@@]1(C)CC[C@H]2[C@](C)(CCC(C(C)C)=C[C@H]21)O
|
| InChi Key |
IWQURBSTAIRNAE-KBXIAJHMSA-N
|
| InChi Code |
InChI=1S/C15H26O2/c1-10(2)11-5-7-14(3,16)12-6-8-15(4,17)13(12)9-11/h9-10,12-13,16-17H,5-8H2,1-4H3/t12-,13-,14+,15+/m1/s1
|
| Chemical Name |
(1S,3aR,4S,8aR)-1,4-dimethyl-7-propan-2-yl-2,3,3a,5,6,8a-hexahydroazulene-1,4-diol
|
| Synonyms |
1αH,5αH-Guaia-6-ene-4β,10β-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1952 mL | 20.9758 mL | 41.9516 mL | |
| 5 mM | 0.8390 mL | 4.1952 mL | 8.3903 mL | |
| 10 mM | 0.4195 mL | 2.0976 mL | 4.1952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
